510(k) device
Oves Cervical Cap
Veos , Ltd. · Cap, Cervical (HDR, Class II) · First FDA decision Mar 21, 2000, newest Mar 21, 2000Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Oves"
MAUDE reports
0
Brand "Oves", since 2015
PubMed studies
17
Mentioning "Oves"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Oves Cervical Cap
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- OVES CERVICAL CAP510(k)
K993953 · Decided Mar 21, 2000 · 120 days after receipt
Device type: Cap, Cervical (HDR) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Positron Emission Tomography (FDG) for Cervical CancerNational analysisReview closedCAG-00181R2Updated Sep 21, 2026
- Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular CancersNational analysisReview closedCAG-00181NUpdated Sep 21, 2026
- Screening Pap Smears and Pelvic Examinations for Early Detection of Cervical or Vaginal CancerNational determinationOn the books210.2Updated Sep 30, 2025
- FDG PET for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers (Replaced with Section 220.6.17) - RETIREDNational determinationOn the books220.6.14Updated Jun 7, 2024
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
- Cervical FusionLocal determinationIn effectL39770Wellpoint FederalUpdated Jul 16, 2026
- Cervical FusionLocal determinationIn effectL39788WPS Insurance CorporationUpdated May 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Oves", any status and sponsor, newest update first.
No registered device study names "Oves".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Oves", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code HDR
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Oves"[tiab]. The summary above synthesizes these.
- Mapping the Direction of Nucleocytoplasmic Transport of Glucocorticoid Receptor (GR) in Live Cells Using Two-Foci Cross-Correlation in Massively Parallel Fluorescence Correlation Spectroscopy (mpFCS).
Nikolik SN, Oasa S, Krmpot AJ, et al. · Anal Chem · 2023Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Proteomic characterization of the internalization of Opisthorchis viverrini excretory/secretory products in human cells.
Chaiyadet S, Smout M, Laha T, et al. · Parasitol Int · 2017
- Lipophilic Magnetic Photonic Nanochains for Practical Anticounterfeiting.
Li G, Luo W, Che Z, et al. · Small · 2022
- Co-occurrence of opisthorchiasis and diabetes exacerbates morbidity of the hepatobiliary tract disease.
Chaidee A, Onsurathum S, Intuyod K, et al. · PLoS Negl Trop Dis · 2018Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Opisthorchis viverrini excretory/secretory products induce toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte.
Ninlawan K, O'Hara SP, Splinter PL, et al. · Parasitol Int · 2010Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
Karnon J, Brennan A, Pandor A, et al. · Curr Med Res Opin · 2005Comparative Study, Research Support, Non-U.S. Gov't
- Oves contraceptive cap: short-term acceptability, aspects of use and user satisfaction.
Roizen J, Richardson S, Tripp J, et al. · J Fam Plann Reprod Health Care · 2002Evaluation Study, Research Support, Non-U.S. Gov't
- Origanum vulgare mediated green synthesis of biocompatible gold nanoparticles simultaneously possessing plasmonic, antioxidant and antimicrobial properties.
Benedec D, Oniga I, Cuibus F, et al. · Int J Nanomedicine · 2018
- Opisthorchis viverrini Proteome and Host-Parasite Interactions.
Suttiprapa S, Sotillo J, Smout M, et al. · Adv Parasitol · 2018Review
- Tetraspanins from the liver fluke Opisthorchis viverrini stimulate cholangiocyte migration and inflammatory cytokine production.
Ruangsuwast A, Smout MJ, Brindley PJ, et al. · Folia Parasitol · 2023
- Excretory/secretory products of the carcinogenic liver fluke are endocytosed by human cholangiocytes and drive cell proliferation and IL6 production.
Chaiyadet S, Smout M, Johnson M, et al. · Int J Parasitol · 2015Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Correction: Oves M, et al. Graphene Decorated Zinc Oxide and Curcumin to Disinfect the Methicillin-Resistant Staphylococcus aureus. Nanomaterials 2020, 10(5), 1004.
Oves M, Rauf MA, Ansari MO, et al. · Nanomaterials (Basel) · 2020Published Erratum
Other devices of this type
Also filed under product code HDR.
- Béa Applicator (BAP-GB-01)Stepone Fertility Ltd (T/A Béa Fertility) · 510(k) 2025
- FERTI-LILY Conception CupRosesta Medical BV · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.